Sutro strikes a $40M China deal as it looks to push ahead of a crowded pack
In the nearly 20 years since it spun out of Stanford, Sutro Biopharma’s greatest financial success has been the other company that uses its underlying …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
